Lexicon Pharmaceuticals (LXRX)
(Real Time Quote from BATS)
$1.19 USD
-0.03 (-2.46%)
Updated Sep 19, 2025 01:58 PM ET
2-Buy of 5 2
F Value A Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LXRX 1.19 -0.03(-2.46%)
Will LXRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LXRX
Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates
LXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
KURA Stock Rises More Than 15% This Past Week: Here's Why
Other News for LXRX
Anti-Aging Market Surges as $101M Competition Drives Demographic Revolution
Is LXRX likely to continue higher? Crossed Above 20 Day Moving Average shows up after rocketing 11.93%
MACD Bearish Centerline Cross appears for LXRX after 0.91% move
Lexicon Pharmaceuticals: Promising Phase 2b Results for Pilavapadin Support Buy Rating
20 Day Moving Average Resistance appears for LXRX after 1.79% move